Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Clinical experience with PRLX93936 underscores the ceiling for systemic dosing, as a phase I trial was terminated early when patients experienced severe, intolerable toxicity at very low doses (93), revealing an exceptionally narrow therapeutic index
RT-qPCR assay showed that RGDV infection significantly increased the expression of Hsp70 in the male reproductive organ (Fig
For these patients, recruiting cytotoxic T cells into the tumor microenvironment can significantly improve the effectiveness of ICIs
All cell lines were confirmed to be free of Mycoplasma at 1-month intervals and never tested positive
Further research on biomarkers is a promising direction for the development of new therapeutic strategies
US$ 29.52
US$ 25.57
US$ 22.88
US$ 24.38
